In the absence of a related donor, unrelated cord blood transplant (CBT) may be a potential option for patients with a primary immune deficiency (PID). Most published experience consists of single-center data using multiple preparative regimens and GVHD prophylaxis. We report the results of a multicenter prospective trial of unrelated CBT for PID. A total of 24 children with PID, with a median age of 1 year (range: 0.23-7.81 years) and a median weight of 10.5 kg (range: 4-24.4 kg) received unrelated CBT between 1999 and 2003. All patients received a fully ablative conditioning regimen with identical GVHD prophylaxis and supportive care. Most patients (79%) received a 1 or 2 HLA Ag-mismatched cord unit with a median nucleated cell infused of 9.3 Â 10 7 /kg (range: 1.0-31.2) and a median CD34 of 2.7 Â 10 5 /kg 2.9 (range: 0.6-84.5). The cumulative incidence of neutrophil engraftment by day 42 was 58% (95% CI: 38-79%) at a median of 19 days. Cumulative incidence estimates of grade III-IV acute GVHD at day 100 and chronic GVHD at 1 year were 29% (95% CI: 10-48%) and 24% (95% CI: 3-44%), respectively. The probability of survival at 180 days and 1 year was 66.7% (95% CI: 44.3-81.7%) and 62.5% (95% CI: 40.3-78.4%), respectively. Unrelated CBT should be considered in children with PID.
Background
Stem cell transplant is an established therapy for primary immune deficiencies (PIDs) since the 1960s. 1 The best results have been obtained with HLA-identical sibling transplants. 2 Promising results have been reported using haplo-identical donors in children with a SCID, although immune reconstitution after such transplants is often delayed for 3-6 months. 3 For patients with other types of immune deficiency, an unrelated BM transplant remains the only potential therapeutic option. Despite the expansion of unrelated donor registries, a significant number of patients lack the availability of an appropriately HLAmatched donor. In addition, an unrelated donor transplant is associated with significant risk of GVHD. 4 Partially HLA-matched cord blood is an established alternative for children with malignant and nonmalignant diseases who lack appropriately matched unrelated donors. 5, 6 Cord blood transplant (CBT) has the potential advantage of being rapidly available, of having a lower risk of viral contamination and a lower risk of GVHD, thus permitting less stringent HLA matching. Several case reports and single-institution studies have reported on the use of unrelated CBT in children with an immune deficiency. 2, [7] [8] [9] [10] Those studies use different preparative regimens and GVHD prophylaxis, which makes the results difficult to interpret. The Cord Blood Transplantation Study (COBLT) is a prospective study sponsored by the National Institute of Health to evaluate the feasibility and safety of CBT in children and adults with malignant and nonmalignant diseases. All patients received a uniform preparative regimen and GVHD prophylaxis. We report in this article, the results of 24 children with a PID who were enrolled in the COBLT trial.
Materials and methods
The COBLT study is a multi-institutional trial of CBT sponsored by the NHLBI (National Heart, Lung and Blood Institute) branch of the National Institute of Health. A total of 364 adults and children were enrolled in the study between 1999 and end of 2003. The protocol was approved by the IRB (Institutional Review Board) of all participating centers. The data of the study were made available by NHLBI for analysis through a limited data agreement with Vanderbilt University. The analysis was approved by the IRB of the Vanderbilt University Medical Center.
Eligibility
A total of 24 patients with a PID who lacked an HLAmatched related donor were enrolled in the immunedeficiency strata. Patients who had undergone an allogeneic transplant in the last 12 months were excluded. All patients who had adequate organ function were included. Organ function requirement included a left ventricular ejection fraction 440%, a creatinine clearance of 450% of the lower limit for age, liver enzymes of o5 times the upper limit of normal and bilirubin o2.5 mg per 100 ml, and pulmonary function tests of 445% predicated, or an oxygen saturation of 485% under room conditions if unable to perform pulmonary function testing. Patients with uncontrolled viral, fungal or bacterial infections were ineligible. Patients with familial hemophagocytic lymphohistiocytosis (HLH) with abnormal brain MRI, or neurological symptoms, or 47/mm 3 lymphocytes plus monocytes in the cerebrospinal fluid were not eligible.
Only patients receiving one cord blood unit (CBU) were eligible. Searches for CBU were conducted using low/ intermediate-resolution molecular typing for HLA class I (A and B) and high-resolution molecular typing for HLA DRB1. Retrospective high resolution for HLA class I was performed on some CBUs. Owing to the small number of patients in this study and the small number of units having retrospective HLA typing, only original HLA typing was used in this analysis. Selection of the unit was on the basis of the highest number of nucleated cell count provided and matching at a minimum of 4/6 HLA loci. The selected CBU was required to provide a minimum of 1 Â 10 7 /kg total nucleated cell (TNC) before cryopreservation per kg of recipient weight.
Transplant procedure
The conditioning regimen consisted of oral BU 20-40 mg/ m 2 per dose, depending on patients' age, for 16 doses on days À9 through to À6, CY 50 mg/kg per dose IV on days À5 through to À2 and antithymocyte globulin (equine) 30 mg/kg/dose IV on days À3 through to À2. BU pharmacokinetics were obtained after the first dose and an adjustment was made to obtain a concentration-steady state of 600-900 ng/ml. Patients with HLH received etoposide 300 mg/m 2 on days À5 through to À3. All patients received phenytoin during BU administration for seizure prophylaxis and mesna during CY therapy to prevent hemorrhagic cystitis. Methylprednisolone, acetaminophen and diphenhydramine were given before and during ATG therapy. The cord blood was thawed, washed and infused on day 0 after premedication with 1 mg/kg of methylprednisolone.
GVHD prophylaxis consisted of methylprednisolone 0.5 mg/kg twice daily on day þ 1 through to þ 4 and then 1 mg/kg twice daily from day þ 5 to day þ 19 or until the first day on which the ANC reached 500/ml, at which time the dose was tapered at the rate of 0.2 mg/kg/week. CYA was started on day À3 and continued until at least day 180. Thereafter, the dose was tapered at the rate of 5% of the initial dose per week if the recipients had no evidence of GVHD.
Study end point
The primary end point of the study was survival at 180 days after transplantation. The secondary end points included engraftment (neutrophil and plt), acute and chronic GVHD and regimen-related morbidity and mortality. Neutrophil engraftment was defined as achieving an ANC of at least 500/ml for three consecutive measurements on different days, and demonstrated a donor chimerism of 490%. Primary graft failure was defined as the failure to attain neutrophil engraftment by day 42. Patients who survived to day 14 but died before neutrophil engraftment were classified as primary graft failures. Secondary graft failure was defined as a loss of neutrophil engraftment. The plt engraftment date was defined as the first of three consecutive days, with a plt count 420 000/ml unsupported by plt transfusion for a minimum of 7 days. The time to neutrophil or plt engraftment was defined as the time from transplantation to the first day of engraftment.
Acute GVHD assessments were carried out every 7 days up to day 100 after CBT, and on day 120 and day 150 after CBT. The grading of acute GVHD followed the GVHD consensus-grading scheme. 11 An algorithm calculated the maximum GVHD clinical grade on the basis of weekly organ staging in the skin, upper and lower gastrointestinal tract and liver. This calculated organ stage was decreased by one stage if a listed specific differential diagnosis was reported for either gastrointestinal tract or liver. An independent panel reviewed all weekly records and assigned each patient a final maximum grade, similar to the methods described by Weisdorf et al.
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Statistical analyses
The Kaplan-Meier method was used to calculate OS. Cumulative incidence (CINC) function was used to estimate rates of neutrophil recovery, plt engraftment and acute and chronic GVHD, considering death as their competing event. A proportional subdistribution hazards regression model was used to assess the effect of baseline characteristics on outcomes. 12 Multivariable modeling was not presented because of the small sample size. All analyses were performed using R version 2.7.1 with survival and cmprsk packages.
Results
Study population
A total of 24 patients with an immune deficiency were enrolled in the study, of which 19 were male and 5 were female, and 17 were Caucasian. Baseline characteristics are described in Table 1 . The median age at the time of transplant was 1 year (range: 0.23-7.81 years). The majority of patients (88%) had a performance status of X90%. A total of nine patients (37.5%) were CMV seropositive. The primary diagnosis was the WAS (WiskottAldrich syndrome) (n ¼ 5), HLH (n ¼ 5), SCID (n ¼ 4), a combined immune deficiency (n ¼ 3), a common variable immune deficiency (n ¼ 3), the Omenn syndrome (n ¼ 2), and one each of Cartilage-hair hypoplasia and the X-linked lymphoproliferative syndrome. Using original HLA typing, 
Engraftment
The CINC of neutrophil recovery at day 42 was 0.58 (95% CI: 0.38-0.79) (Figure 1a) . A total of 14 of 23 (61%) evaluable patients had neutrophil engraftment at a median time of 19 days (range: 12-31 days). The incidence of neutrophil engraftment was found to be significantly associated with higher TNC dose per kg (P ¼ 0.001) and the CD34 þ dose (P ¼ 0.001). Other factors including age, sex, ethnicity, HLA match and recipient CMV status were not significantly associated with the incidence of neutrophil engraftment. Although nine patients experienced graft failure as defined by the study, five patients (patient 8, 9, 13, 15 and 24) had neutrophil recovery and maintained donor chimerism between 70 and 100% on last evaluation. Owing to the fact that those patients did not achieve 490% donor chimerism on day 42, they were classified as graft failure per study. One patient with SCID engrafted after a second unrelated CBT (patient 4). The CINC of plt engraftment at day 180 is 0.63 (95% CI: 0.42-0.83) (Figure 1b) . In all, 15 of 24 (62.5%) patients achieved plt engraftment at a median of 51 days (range: 15-99 days). At 1 year after transplantation, 77% of surviving patients had achieved a plt count greater than 20 000/ml. There was significant association between plt engraftment and CD34 þ dose (P ¼ 0.002). Other factors including age, weight, sex, ethnicity, HLA match, CMV status and TNC dose per kg did not significantly affect plt recovery.
Acute and chronic GVHD
The CINC of grade II-IV acute GVHD at day 100 was 0.46 (95% CI: 0.25-0.67). Seven patients had grade III-IV acute GVHD. The CINC of grade III-IV at day 100 was 0.29 (95% CI: 0.10-0.48) (Figure 1c ). The incidence of grade III-IV acute GVHD was found to be significantly associated with higher TNC dose per kg (P ¼ 0.001) and the CD34 þ dose (P ¼ 0.002). Other factors including age, sex, ethnicity, HLA match and recipient CMV status were not significantly associated with the incidence of grade III-IV acute GVHD. Five patients out of 17 who survived for more than 100 days with sustained donor engraftment developed chronic GVHD. There were two patients with extensive chronic GVHD and three with limited chronic GVHD. The CINC for chronic GVHD at 1 year was 0.24 (95% CI: 0.03-0.44) (Figure 1d ). (Figure 2 ). The median follow-up for surviving patients was 26 months (range: 13.5-48.6 months). Patient's age, sex, ethnicity, HLA match, recipient CMV status, TNC and CD34 þ dose were not significantly associated with OS. Nine patients died, three secondary to graft failure (one each of SCID, HLH and CVID), three secondary to acute GVHD (one each of SCID, HLH and the Omenn syndrome) and three secondary to multiorgan failure (one each of HLH, SCID and the Omenn syndrome). All patients with WAS are alive. Details of patient's outcomes are described in Table 2 .
Survival
Discussion
Allogeneic stem cell transplant from matched related donors was shown to cure PID in the late 1960s. In patients without a matched sibling, the choice is between T-cell-depleted mismatched related donor transplant or unrelated donor stem cell transplant. Finding a fully matched unrelated donor can take several weeks and some patients, especially those with mixed race or minorities, might not have a fully matched donor. The advantages of unrelated cord blood are that it is readily available and full HLA matching might not be required. Another advantage is the potential for less GVHD after a CBT when compared with an unrelated donor BM transplant. There are few single-center reports of unrelated CBT in children with an immune deficiency. Knutsen et al. 8 reported on eight children with various immune deficiencies who received a reported on 14 children with PID who received either no preparative regimen (n ¼ 4) or chemotherapy-based regimens. The OS was 83%, with two reported deaths. One died from multisystem organ failure and another from viral pneumonia. Tsuji et al. 13 reported on seven patients with SCID (n ¼ 5) and WAS (n ¼ 2) who received UCB transplant at three Japanese centers. All patients received either TBI or a BU-based preparative regimen and five survived with donor engraftment. Diaz et al.
2 recently reported the results of 15 UCB transplants from three centers in Spain. A majority of the patients had SCID (n ¼ 11) and most patients received a fully ablative regimen (n ¼ 13). 2 All patients engrafted, and the survival was 73%. Three patients died secondary to GVHD (n ¼ 3) and one died from interstitial pneumonitis. Patients in those reports received different preparative regimens and GVHD prophylaxis. Our report represents the first prospective multicenter trial with all patients receiving an identical preparative regimen, GVHD prophylaxis and supportive care.
In our study, the CINC of neutrophil engraftment is 58%, with 9 of 24 patients experiencing graft failure and three patients dying secondary to graft failure. This rate is lower than those described in other groups with CBT for immune deficiency. 2, 8 These results are in part due to the more strict definition of graft failure. Five of our patients achieved neutrophil recovery with 70-100% donor chimerism, but it occurred on or after day 42. This engraftment rate is lower than the 7% rate of graft failure described with matched unrelated donor transplant but slightly better than the 30% with mismatched related donors. 4 Similar to the results described by others, engraftment in our patients was Unrelated cord blood transplant for immune deficiency H Frangoul et al significantly associated with the infusion of a higher TNC and CD34 cell dose. 14 Owing to the small number of patients with a specific diagnosis, a subanalysis could not be performed in our patient population.
One of the potential advantages of using unrelated CBT is the lower rate of GVHD. A total of 73% of patients with an immune deficiency, who received an unrelated donor BM transplant, developed acute GVHD. 4 This percentage is higher than that which we observed in our patients, although the majority of our patients received mismatched CBUs. We found a significant correlation between a higher TNC and CD34 þ cell dose and the rate of severe grade II-IV GVHD. This observation has not been reported and it is worth evaluating in a larger cohort of patients. The rate of chronic GVHD in our patient is also relatively low, with 5 of 17 patients developing chronic GVHD and only 2 having extensive chronic GVHD. The rate of chronic GVHD in our report is comparable with that which has been reported in fully matched unrelated donor transplant. 4 The OS in our report compares favorably with reports from single institutions using unrelated CBT in PID. 2, 7, 8, 10 Among the patients with HLH, two of five patients are alive and fully engrafted. These results are similar to those in a recently published report using a similar preparative regimen. 15 The outcome in patients with WAS is especially positive, with all patients alive with 75-100% donor engraftment without chronic GVHD. Recent reports have shown decreased TRM and improved survival using reduced intensity-conditioning regimens in patients with PID receiving unrelated BM transplant. This approach should be studied in recipients of unrelated CBT to potentially decrease TRM and improve OS. 16, 17 The result of this multicenter trial shows that unrelated CBT represents a potential therapeutic option for patients with PID. One limitation of our report is the lack of detailed T-cell and B-cell numbers, as well as a function analysis after transplant. 
